News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
《業績》三生製藥(01530.HK)全年純利84.82億人民幣增306% 末期息派25港仙
三生製藥(01530.HK)公布2025年度業績，收入176.96億人民幣(下同)，按年增加94.3%，主要由於與輝瑞就集團突破性PD-1/VEGF雙 抗707達成的授權交易產生的許可收入。錄得純利84.82億元，增長305.8%，每股盈利3.51元。末期息維持25港仙。年內，毛利163.47億元，增加108.8%，毛利率由86%增至92.4%。(de/d)...
Reset
Send
The window will close in 5 seconds
《業績》三生製藥(01530.HK)全年純利84.82億人民幣增306% 末期息派25港仙
Close
Recommend
24
Positive
30
Negative
13
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

三生製藥(01530.HK)  +0.060 (+0.237%)    Short selling $365.07M; Ratio 86.993%   公布2025年度業績，收入176.96億人民幣(下同)，按年增加94.3%，主要由於與輝瑞就集團突破性PD-1/VEGF雙 抗707達成的授權交易產生的許可收入。錄得純利84.82億元，增長305.8%，每股盈利3.51元。末期息維持25港仙。

Dividend History
Announce DateEventParticular
2025/11/20SpecialDistribution in Specie: Mandi Inc. share
2025/08/29InterimNo Dividend
2025/03/25FinalD:HKD 0.2500
2024/08/22InterimNo Dividend

年內，毛利163.47億元，增加108.8%，毛利率由86%增至92.4%。(de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)
AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.